RE: CHART23 Jul 2021 09:57
Here is the email I received last June (13 months ago) in response to a stroppy email I sent to Dr Parker. (Worth a re- read).
Dear Mr...........,
Very many thanks for your email and I note your concerns. We will be making a trading statement, as we usually do following the year-end and we expect that this will be done via the new platform https://www.investormeetcompany.com/, which will allow a more interactive session with shareholders. We will be announcing the date of the Trading Statement in advance.
I understand your frustration with the news flow, however, you must recall that all of our programmes are, or have been, partnered at some stage as a means of making progress for remarkably little cost, in line with the amount which we have raised over the years from shareholders (which, in comparison with most of the companies quoted in the list below, is very small). The price that is paid, however, is that we lose control of the timeframe with which work is done - think of the delay in the publication of lupus data from the TYK2 programme since they are owned by the US Department of Defence and not by Sareum.
Most notably, do recall that Sareum is the minority partner with Cancer Research for the chk1 programme and not a party to the licensing contract with Sierra - unfortunately we are, therefore, a spectator in the current progress of the drug and we have always ensured that our shareholders are informed of any developments with the shortest possible delay; I have always interacted with both Sierra and CPF to remind them that, as a listed company, Sareum has responsibilities to its shareholders too.
I am a firm believer in open interaction with shareholders and happy to help with concerns as they arise. I am not, however, in the business of “ramping” the stock without justification, nor running the risk of unnecessary interference from either the AiM team or the Takeover Panel - I am afraid that your suggestion of announcing either CDAs or closed periods might very well trigger either or both institution to seek clarification, which would not be the best use of a small management team’s time.
I hope that this is helpful to you.
With best regards,
Dr Stephen Parker